The 19 most recent market catalysts affecting $GSK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
GSK Says Health Canada Accepted Jemperli For Accelerated Review In Genetic Subtype Of Locally Advanced Rectal Cancer
The acceptance of Jemperli for accelerated review by Health Canada is a significant positive development for GSK. Accelerated review pathways are typically granted for drugs that a…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is GSK Stock Gaining Monday?
GSK released compelling Phase 3 data for Risvutatug Rezetecan (Ris-Rez) in small cell lung cancer, showing a 54% reduction in mortality risk and significantly extended median survi…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows
GSK reported impressive interim data for Jideytro in the ARROS-1 trial for ROS1-positive NSCLC. The 94% objective response rate and 90% progression-free rate at 12 months, along wi…
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 55
GSK Says Plans To Stop Manufacturing At Co's Dresden, Germany Flu Vaccine Manufacturing Site In Summer 2027
GSK has announced plans to discontinue flu vaccine manufacturing at its Dresden, Germany facility by summer 2027. This move suggests a strategic re-evaluation of its global manufac…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors
GSK has reported strong mid-stage results for its mRNA seasonal influenza vaccine, showing superior immune responses against all tested strains compared to existing licensed vaccin…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Relation Expands GSK Collaboration Worth Up To $110M In Upfront And Milestone Payments To Generate Large-Scale Human Cellular Perturbation Datasets For Disease Biology Research
This headline is a significant corporate catalyst for both Relation Therapeutics and GSK. For Relation, it provides substantial funding and validation for their cellular perturbati…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026
GSK, through its joint venture ViiV Healthcare, announced positive clinical trial results for Cabenuva, a long-acting injectable HIV treatment, showing its superiority to daily ora…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals
GSK announced better-than-expected second-quarter earnings and revenue, driving its stock up. The core of this filing is the launch of a $2.52 billion cost-savings program, 'Accele…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 55
GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.
GSK announced a £400 million investment to build a new R&D center in Cambridge, UK, consolidating its existing R&D operations in the area. This move is significant as it underscore…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
GSK shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY31 sales guidance above estimates.
This headline is a major positive catalyst for GSK. Better-than-expected Q2 results indicate strong current operational performance, while the raised FY31 sales guidance provides a…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est
GSK has announced an ambitious revenue projection for FY2031, forecasting over $53.204 billion, which is a significant uplift compared to the $45.690 billion analyst estimate. This…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate
GSK announced its Q2 earnings, reporting adjusted EPS of $1.35, which significantly beat the analyst consensus of $1.27. Additionally, the company's sales of $11.280 billion surpas…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma
GSK's licensor, Hansoh Pharma, announced positive results from a second Phase III trial for Ris-Rez in China, specifically for relapsed osteosarcoma, which met its primary endpoint…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 55
GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled Syringe
GSK Canada announced the approval of its Shingrix vaccine in a prefilled syringe format. This development is significant because it streamlines the vaccine administration process b…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer
GSK has secured early FDA approval for Jideytro, a ROS1 selective inhibitor, for a specific type of non-small cell lung cancer. This approval is significant because it comes ahead …
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 75
GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.
GSK has decided to discontinue the development of Camlipixant, a drug intended for refractory chronic cough, after it failed to achieve statistical significance in its CALM-1 and C…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 75
Disappointing Data Prompts GSK to Drop Cough Drug Development
GSK's decision to halt the development of camlipixant for refractory chronic cough is a negative catalyst for the company. The inconsistent Phase 3 trial data, particularly the fai…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 85
GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials
GSK has decided to stop further development of Camlipixant, its investigational drug for refractory chronic cough, following the failure of its 25mg twice-daily dose to achieve sta…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.